-
公开(公告)号:US06919369B2
公开(公告)日:2005-07-19
申请号:US10224114
申请日:2002-08-19
申请人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
发明人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
IPC分类号: C07D333/34 , A61K31/18 , A61K31/196 , A61K31/216 , A61K31/381 , A61P7/02 , A61P9/10 , C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
CPC分类号: C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
摘要: Compounds having the structure shown below are useful to inhibit serine protease enzymes, such as TF/factor VIIa, factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
摘要翻译: 具有如下结构的化合物可用于抑制丝氨酸蛋白酶,例如TF /因子VIIa,因子Xa,凝血酶和激肽释放酶。 这些化合物可用于预防和/或治疗凝血障碍的方法。
-
公开(公告)号:US06472393B1
公开(公告)日:2002-10-29
申请号:US09509104
申请日:2000-03-21
申请人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
发明人: Ignacio Aliagas-Martin , Dean R. Artis , Michael S. Dina , John A. Flygare , Richard A. Goldsmith , Regina A. Munroe , Alan G. Olivero , Richard Pastor , Thomas E. Rawson , Kirk D. Robarge , Daniel P. Sutherlin , Kenneth J. Weese , Aihe Zhou , Yan Zhu
IPC分类号: A61K3118
CPC分类号: C07C257/18 , C07C311/05 , C07C311/08 , C07C311/13 , C07C311/18 , C07C311/29 , C07C311/51
摘要: Compounds having the structure shown below wherein A, B, N1, N2, X, Y, Q, R2, R5 and R6 are as defined herein are useful to inhibit serine protease enzymes, such as TF/factor VIIa factor Xa, thrombin and kallikrein. These compounds may be used in methods of preventing and/or treating clotting disorders.
摘要翻译: 具有下述结构的化合物其中A,B,N1,N2,X,Y,Q,R2,R5和R6如本文所定义,可用于抑制丝氨酸蛋白酶,如TF /因子VIIa因子Xa,凝血酶和激肽释放酶 。 这些化合物可用于预防和/或治疗凝血障碍的方法。
-
公开(公告)号:US08232273B2
公开(公告)日:2012-07-31
申请号:US12641141
申请日:2009-12-17
申请人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Peter Czabotar , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Lisa A. Hasvold , Andrew M. Petros , Andrew J. Souers , Zhi-Fu Tao , Le Wang , Xilu Wang , Kurt Deshayes
发明人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Peter Czabotar , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Lisa A. Hasvold , Andrew M. Petros , Andrew J. Souers , Zhi-Fu Tao , Le Wang , Xilu Wang , Kurt Deshayes
IPC分类号: A61K31/5377 , C07D413/14
CPC分类号: C07D417/14 , C07D471/06 , C07D473/00 , C07D487/04 , C07D495/04 , C07D513/04 , C07D513/06
摘要: In one aspect, the present invention provides for a compound of Formula I in which the variable X1a, X1b, X1c, X1d, Q, A, R1, B, L, E, and the subscripts m and n have the meanings as described herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
摘要翻译: 一方面,本发明提供了其中变量X1a,X1b,X1c,X1d,Q,A,R1,B,L,E和下标m和n具有如本文所述的含义的式I化合物 。 另一方面,本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症(例如,癌症,血小板增多症等)的方法 的Bcl-2抗凋亡蛋白,例如抗凋亡Bcl-xL蛋白。
-
公开(公告)号:US08114893B2
公开(公告)日:2012-02-14
申请号:US12641063
申请日:2009-12-17
申请人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Carl Steven Rye , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Andrew M. Petros , Andrew J. Souers , Peter Czabotar
发明人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Carl Steven Rye , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Andrew M. Petros , Andrew J. Souers , Peter Czabotar
IPC分类号: C07D417/14 , A61K31/5377 , A61K31/538 , A61K31/496 , A61K31/498 , A61K31/4709
CPC分类号: C07D417/14 , C07D417/12 , C07D487/04
摘要: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
摘要翻译: 一方面,本发明提供式I化合物,其中在式I中,变量X1,X2a,X2b,X2c,R1,B,L,E,A和下标n如本文所定义。 另一方面,本发明提供包含式I化合物的药物组合物以及使用式I化合物治疗以表达或过表达为特征的疾病和病症(例如,癌症,血小板增多症等)的方法 的Bcl-2抗凋亡蛋白,例如抗凋亡Bcl-xL蛋白。
-
公开(公告)号:US20110077265A1
公开(公告)日:2011-03-31
申请号:US12598027
申请日:2008-04-29
申请人: John A. Flygare , Frederick Cohen , Kurt Deshayes , Michael F. T. Koehler , Lewis J. Gazzard , Lan Wang , Chudi Ndubaku
发明人: John A. Flygare , Frederick Cohen , Kurt Deshayes , Michael F. T. Koehler , Lewis J. Gazzard , Lan Wang , Chudi Ndubaku
IPC分类号: A61K31/437 , C07D417/14 , C07D513/04 , C07D403/12 , C12N5/071 , C07K2/00 , A61K31/4545 , A61K31/433 , A61K31/4025 , A61K31/427 , A61P35/00
CPC分类号: C07D417/14 , C07D207/16 , C07D519/00
摘要: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds having the general formula U1-M-U2 wherein M is a linking group covalently joining R2, R3, R4 or R5 of U1 to an R2, R3, R4 or R5 group of U2; U1 and U2 have the general formula (I) and G, X1, X2, R2, R3, R3′, R4, R4′ and R5, are as described herein.
摘要翻译: 本发明提供了可用作治疗恶性肿瘤的治疗剂的新的IAP抑制剂,其中具有通式U1-M-U2的化合物,其中M是共价连接U1的R2,R3,R4或R5的连接基团与R2,R3 ,R4或R5组的U2; U1和U2具有通式(I),G,X 1,X 2,R 2,R 3,R 3',R 4,R 4'和R 5如本文所述。
-
公开(公告)号:US20100256115A1
公开(公告)日:2010-10-07
申请号:US12727218
申请日:2010-03-18
申请人: Frederick Cohen , Kurt Deshayes , Wayne J. Fairbrother , Bainian Feng , John A. Flygare , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui
发明人: Frederick Cohen , Kurt Deshayes , Wayne J. Fairbrother , Bainian Feng , John A. Flygare , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui
IPC分类号: A61K31/55 , C07D209/48 , A61K31/4035 , C07D277/06 , A61K31/427 , C07D487/04 , C07D231/40 , C07D285/06 , A61K31/4155 , A61K31/433 , C07D207/323 , A61K31/40 , C07D249/06 , A61K31/4192 , C07D261/14 , A61K31/42 , C07D257/06 , A61K31/41 , C07D271/04 , A61K31/4245 , C07D417/04 , A61K31/4439 , A61P35/00 , C12N5/071
CPC分类号: C07D417/14 , A61K31/55 , A61K38/177 , C07D403/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D495/04 , C07D513/04 , C07K5/06026 , C07K5/0806 , C07K5/0827 , C07K7/06 , C12N5/0693
摘要: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein.
摘要翻译: 本发明提供了可用作治疗恶性肿瘤的治疗剂的新的IAP抑制剂,其中化合物具有通式I:其中X,Y,A,R 1,R 2,R 3,R 4,R 4',R 5,R 5',R 6和 R6'如本文所述。
-
公开(公告)号:US06388131B2
公开(公告)日:2002-05-14
申请号:US09872463
申请日:2001-05-31
IPC分类号: A61K3136
CPC分类号: C07C311/21
摘要: The invention provides compounds, compositions and methods relating to novel electrophilic aromatic derivatives and their use as pharmacologically active agents. The compositions find particular use as pharmacological agents in the treatment of disease states, particularly cancer, psoriasis, vascular restenosis, infections, atherosclerosis and hypercholesterolemia, or as lead compounds for the development of such agents. The compositions include compounds of the general Formula I:
-
公开(公告)号:US08835393B2
公开(公告)日:2014-09-16
申请号:US13057176
申请日:2009-07-23
申请人: Danette Dudley , John A. Flygare , Chudi Ndubaku
发明人: Danette Dudley , John A. Flygare , Chudi Ndubaku
IPC分类号: A61K38/06 , C07K5/08 , A61P35/00 , C07D403/12 , C07D513/04 , C07D207/16 , C07K5/083
CPC分类号: C07D403/12 , C07D207/16 , C07D513/04 , C07K5/0804
摘要: The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein. The compouds of the invention may be used to induce apoptosis in cells (or sensitise cells to apoptosis) in which IAPs are overexpressed or otherwise implicated in resistance to normal apoptotic processes. Accordingly, the compounds may be provided in pharmaceutically acceptable compositions and used for the treatment cancers.
摘要翻译: 本发明提供了具有以下通式的IAP抑制剂的新化合物:其中X1,X2,X3,Y,A,R1,R2,R3,R4,R4',R5,R5',R6和R6'如本文所述 。 本发明的化合物可用于诱导细胞凋亡(或致敏细胞凋亡),其中IAP过表达或以其他方式涉及抗正常凋亡过程。 因此,化合物可以以药学上可接受的组合物提供,并用于治疗癌症。
-
公开(公告)号:US08518970B2
公开(公告)日:2013-08-27
申请号:US13347364
申请日:2012-01-10
申请人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Carl Steven Rye , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Andrew M. Petros , Andrew J. Souers , Peter Czabotar
发明人: Jonathan Bayldon Baell , Chinh Thien Bui , Peter Colman , Danette A. Dudley , Wayne J. Fairbrother , John A. Flygare , Guillaume Laurent Lessene , Chudi Ndubaku , George Nikolakopoulos , Carl Steven Rye , Brad Edmund Sleebs , Brian John Smith , Keith Geoffrey Watson , Steven W. Elmore , Andrew M. Petros , Andrew J. Souers , Peter Czabotar
IPC分类号: C07D417/14 , A61K31/5377 , A61K31/538 , A61K31/496 , A61K31/498 , A61K31/4709
CPC分类号: C07D417/14 , C07D417/12 , C07D487/04
摘要: In one aspect, the present invention provides for a compound of Formula I in which in Formula I, the variables X1, X2a, X2b, X2c, R1, B, L, E, A and the subscript n are as defined herein. In another aspect, the present invention provides for pharmaceutical compositions comprising compounds of Formula I as well as methods for using compounds of Formula I for the treatment of diseases and conditions (e.g., cancer, thrombocythemia, etc) characterized by the expression or over-expression of Bcl-2 anti-apoptotic proteins, e.g., of anti-apoptotic Bcl-xL proteins.
-
公开(公告)号:US20120202750A1
公开(公告)日:2012-08-09
申请号:US13356556
申请日:2012-01-23
申请人: Frederick Cohen , Kurt Deshayes , Wayne J. Fairbrother , Bainian Feng , John A. Flygare , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui
发明人: Frederick Cohen , Kurt Deshayes , Wayne J. Fairbrother , Bainian Feng , John A. Flygare , Lewis J. Gazzard , Vickie Hsiao-Wei Tsui
IPC分类号: C07D401/12 , A61K38/06 , A61K31/55 , C12N5/09 , A61K31/42 , A61K31/433 , A61K31/4436 , C07D285/10 , A61K31/426 , C07D261/14 , C07D271/08 , A61K31/415 , A61K31/381 , C07K5/08 , C07D513/04 , A61P35/04 , C07D417/04 , A61K31/4245 , C07D417/12 , C07D277/18 , C07D257/06 , A61K31/41 , C07D249/04 , C07D333/36 , A61K31/506
CPC分类号: C07D417/14 , A61K31/55 , A61K38/177 , C07D403/12 , C07D413/12 , C07D417/04 , C07D417/12 , C07D495/04 , C07D513/04 , C07K5/06026 , C07K5/0806 , C07K5/0827 , C07K7/06 , C12N5/0693
摘要: The invention provides novel inhibitors of IAP that are useful as therapeutic agents for treating malignancies where the compounds have the general formula I: wherein X, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein.
摘要翻译: 本发明提供了可用作治疗恶性肿瘤的治疗剂的新的IAP抑制剂,其中化合物具有通式I:其中X,Y,A,R 1,R 2,R 3,R 4,R 4',R 5,R 5',R 6和 R6'如本文所述。
-
-
-
-
-
-
-
-
-